CN Patent

CN115677676B — 一种治疗银屑病的药物及其制备方法

Assigned to Heilongjiang University of Chinese Medicine · Expires 2024-10-01 · 2y expired

What this patent protects

本发明提供了一种治疗银屑病的药物及其制备方法。本发明所述治疗银屑病的药物为天然产物苯丙烯酸类化合物的衍生物，具有式I所示的结构。本发明化合物具有对于JAK2和TYK2的良好抑制活性，有望发展成为新的银屑病治疗药物。

USPTO Abstract

本发明提供了一种治疗银屑病的药物及其制备方法。本发明所述治疗银屑病的药物为天然产物苯丙烯酸类化合物的衍生物，具有式I所示的结构。本发明化合物具有对于JAK2和TYK2的良好抑制活性，有望发展成为新的银屑病治疗药物。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN115677676B
Jurisdiction: CN
Classification: —
Expires: 2024-10-01
Drug substance claim: No
Drug product claim: No
Assignee: Heilongjiang University of Chinese Medicine
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.